Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
435
datasets available to search
ShareScore release 0.9.0
Dataset results
435 results for “NAFLD”
Inter-Chemical Correlation results for the study: HHEARx2017-1593 (Role of environmental toxicants in modulating disease severity in children with NAFLD)
Title: Role of environmental toxicants in modulating disease severity in children with NAFLD <br>Species: Homo sapiens <br>Number of samples: 436 <br>Number of named analytes: 7 <br>Datasource url: https://hheardatacenter.mssm.edu/PublicFile/ViewPublicFile?projectid=30 <br>
Figure S1. Mediation analysis on the effect of insulin resistance on intraocular pressure. Figure S2. Forest plot showing the OR (95% CI) for EIOP of ALD versus NAFLD and the OR (95% CI) for EIOP of drinkers versus non-drinkers. Abbreviations: OR, odds ratio; CI, confidence interval; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease.
<p>Figure S1. Mediation analysis on the effect of insulin resistance on intraocular pressure.</p> <p>Figure S2. Forest plot showing the OR (95% CI) for EIOP of ALD versus NAFLD and the OR (95% CI) for EIOP of drinkers versus non-drinkers. Abbreviations: OR, odds ratio; CI, confidence interval; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease.</p>
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER St
ClinicalTrials.gov study NCT04216589. IPD Sharing: YES. Countries: 2. Publications: 2.
Dietary Treatment Study of Pediatric NAFLD
ClinicalTrials.gov study NCT02513121. IPD Sharing: YES. Countries: 1. Publications: 9.
Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)
ClinicalTrials.gov study NCT04147195. IPD Sharing: YES. Countries: 3. Publications: 1.
Raw data related to: Randomised Clinical Trial: Calorie Restriction Regimen with Tomato Juice Supplementation Ameliorates Oxidative Stress and Preserves a Proper Immune Surveillance Modulating Mitochondrial Bioenergetics of T-Lymphocytes in Obese Children Affected by Non-Alcoholic Fatty Liver Disease (NAFLD)
<p><strong>Abstract</strong></p> <p>Fatty liver disease is a serious complication of childhood obesity. Calorie-restricted regimen (RCR) is one of the e ective therapy for this condition. Aim of the study was to evaluate the effect of lycopene-rich tomato sauce with oregano and basil extracts in obese children with fatty liver on RCR. 61 obese children with fatty liver were enrolled, 52 completed the study. A randomized cross over clinical trial was performed. Participants were assigned to RCR alone or with a supplement of lycopene-rich tomato juice for 60 days; subsequently, the groups were switched to the alternative regimen for the next 60 days. Reduction in BMI, HOMA-IR, cholesterol, triglycerides, liver size, and steatosis was more profound in tomato-supplemented group. Leptin decreased in both groups whereas adiponectin raised only after tomato supplementation. RCR is associated with the impaired engagement of T-cells glycolysis and proliferation, tomato-supplementation resulted in glycolytic metabolic activation of T-cells. Tomato juice ameliorates glucose and lipid metabolism in obese children, improve oxidative and inflammatory state and modulates the mitochondrial metabolism of T-cells contributing to a maintenance of a proper immune surveillance in children, impaired by RCR. The addition of tomato to RCR could be considered a protective and preventive support to obese child.</p> <p><strong>Progetto giovani ricercatori </strong>[GR-2016-02363725] dal titolo: "Immune Tolerance, Metabolism and Multiple Sclerosis: Novel Molecular Tools to Monitor Disease Pathogenesis and Progression"</p>
oLIVER progress presentation 2022: Identifying biomarkers for diagnosis and treatment evaluation of NAFLD
<p>This is a recorded talk with head of the oLIVER project - Jørgen Kjems, where he presents the latest project progress.</p> <p>The talk was given at one of ODIN's (the Open Discovery Innovation Network) Knowledge Sharing Events in May 2022.</p>
Bacteria-Derived Extracellular Vesicle Microbiome in NAFLD Patients With and Without Obstructive Sleep Apnea
<p>These are the supplementary figures.</p>
NAFLD and diarrhea: a prospective observational study
<p>This is the dataset obtained in the prospective study of the incidence of bile acid diarrhoea in patients with non-alcoholic fatty liver disease NAFLD) conducted at Imperial College London in 2015.</p>
SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
ClinicalTrials.gov study NCT02649465. IPD Sharing: NO. Countries: 1. Publications: 2.
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
ClinicalTrials.gov study NCT01002547. IPD Sharing: NO. Countries: 1. Publications: 1.
Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
ClinicalTrials.gov study NCT03248882. IPD Sharing: YES. Countries: 6. Publications: 2.
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
ClinicalTrials.gov study NCT04944992. IPD Sharing: YES. Countries: 16. Publications: 1.
A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
ClinicalTrials.gov study NCT04048135. IPD Sharing: UNDECIDED. Countries: 2. Publications: 3.
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
ClinicalTrials.gov study NCT01679197. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
ClinicalTrials.gov study NCT01529268. IPD Sharing: YES. Countries: 1. Publications: 2.
Investigation of Synbiotic Treatment in NAFLD
ClinicalTrials.gov study NCT01680640. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Study of Losartan in the Treatment of NAFLD in Children
ClinicalTrials.gov study NCT01913470. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)
ClinicalTrials.gov study NCT03639623. IPD Sharing: NO. Countries: 1. Publications: 2.
6-week Safety and PD Study in Adults With NAFLD
ClinicalTrials.gov study NCT03256526. IPD Sharing: YES. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.